Rayvio_News_Filter
Nov 19, 9:03 PM
$DRTS 🏥
Alpha Tau Medical Ltd. reported interim REGAIN trial results in recurrent glioblastoma showing all eight treated patients alive, median overall survival not reached, 100% objective response rate including five complete responses in the first six evaluable patients, and FDA approval to expand the trial from 10 to up to 20 patients.
Actionable market event
0 replies